Kwint M, et al. – Non–small cell lung cancer (NSCLC) patients diagnosed with synchronous oligometastatic disease who underwent radical treatment of both intrathoracic disease and metastases were examined for their progression free survival (PFS) and overall survival (OS). The aforementioned treatment regimen for a selected group of NSCLC patients with good performance status presenting with synchronous oligometastatic disease resulted in favorable long–term PFS and OS.

Methods

• This observational study incorporated patients with NSCLC and oligometastatic disease at diagnosis, who were treated with radical intent between 2008 and 2016.
• Furthermore, treatment consisted of systemic treatment and radical radiotherapy or resection of the intrathoracic disease.
• Radical or stereotactic radiotherapy, surgical resection or radiofrequency ablation were the treatment of the metastases.

Results

• Experts enrolled ninety-one patients (52% men, mean age 60 years) in good performance status.
• They reported thirty-eight (42%) deaths during follow-up (median follow-up 35 months).
• Lung cancer in all patients, except one was the cause of death.
• Recurrent disease was developed in sixty-three (69%) patients.
• Moreover, eleven recurrences (17%) occurred within the irradiated area.
• The median PFS was 14 months (range 2-89, 95%CI 12-16) and the median OS was 32 months (range 3-89, 95%CI 25-39), for the whole group.
• 85% and 58% were the 1- and 2-year OS rates and the 1- and 2-year PFS rates were 55% and 27%, respectively.